LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Test May Help Detect Kidney Cancer Earlier

By LabMedica International staff writers
Posted on 26 Sep 2018
Image: An ELISA Kit for Kidney Injury Molecule 1 (Kim1) (Photo courtesy of Enzo Life Sciences).
Image: An ELISA Kit for Kidney Injury Molecule 1 (Kim1) (Photo courtesy of Enzo Life Sciences).
Renal cell carcinoma (RCC) has the potential for cure with surgery when diagnosed at an early stage. Kidney injury molecule-1 (KIM-1) has been shown to be elevated in the plasma of RCC patients.

Renal cell carcinoma is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90% to 95% of cases.

Scientists from the Beth Israel Deaconess Medical Center (Boston, MA, USA) and their colleagues conducted a population-based prospective cohort study that included 190 patients who developed renal cell carcinoma within five years (cases) and 190 patients who remained healthy (controls). A risk model that included kidney injury molecule-1 significantly distinguished between cases and controls, compared with a risk model that included known risk factors of renal cell carcinoma, including age, sex, country, BMI and tobacco smoking status. Kidney injury molecule-1 (KIM-1) was measured in in pre-diagnostic plasma.

The team reported that they found that patients who eventually developed renal cell carcinoma had double the concentration of kidney injury molecule-1 in prediagnostic plasma (incidence rate ratio = 1.71 (95% CI, 1.44-2.03). They compared a risk model including known risk factors of RCC (age, sex, country, body mass index and tobacco smoking status), with a risk model additionally including KIM-1 substantially improved discrimination between cases and controls (area under the receiver operating characteristic curve of 0.8 compared to 0.7). High plasma KIM-1 concentrations were also associated with poorer survival.

The authors concluded that plasma KIM-1 concentrations could predict RCC incidence up to five years prior to diagnosis and were associated with poorer survival. Rupal Bhatt, MD, PhD, a medical oncologist and the senior author of the study, said, “Renal cell carcinoma has the potential for cure with surgery when diagnosed at an early stage. Kidney injury molecule-1 has been shown to be elevated in the plasma of renal cell carcinoma patients.” The study was published on September 6, 2018, in the journal Clinical Cancer Research.

Related Links:
Beth Israel Deaconess Medical Center

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more